BR112014010134A2 - inibição da expressão genética viral - Google Patents
inibição da expressão genética viralInfo
- Publication number
- BR112014010134A2 BR112014010134A2 BR112014010134A BR112014010134A BR112014010134A2 BR 112014010134 A2 BR112014010134 A2 BR 112014010134A2 BR 112014010134 A BR112014010134 A BR 112014010134A BR 112014010134 A BR112014010134 A BR 112014010134A BR 112014010134 A2 BR112014010134 A2 BR 112014010134A2
- Authority
- BR
- Brazil
- Prior art keywords
- modified
- sirens
- sirnas
- relates
- inhibition
- Prior art date
Links
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 230000006648 viral gene expression Effects 0.000 title 1
- 241000269400 Sirenidae Species 0.000 abstract 4
- 108020004459 Small interfering RNA Proteins 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 2
- 230000030279 gene silencing Effects 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 239000002777 nucleoside Substances 0.000 abstract 2
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 2
- -1 2-guanidinopropyl Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 108020004999 messenger RNA Proteins 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201107890 | 2011-10-28 | ||
| PCT/IB2012/055915 WO2013061295A1 (en) | 2011-10-28 | 2012-10-26 | Inhibition of viral gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014010134A2 true BR112014010134A2 (pt) | 2019-09-24 |
Family
ID=47326248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014010134A BR112014010134A2 (pt) | 2011-10-28 | 2012-10-26 | inibição da expressão genética viral |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140350080A1 (enExample) |
| EP (1) | EP2771466A1 (enExample) |
| CN (1) | CN104011209A (enExample) |
| AP (1) | AP2014007650A0 (enExample) |
| BR (1) | BR112014010134A2 (enExample) |
| CA (1) | CA2853609A1 (enExample) |
| IN (1) | IN2014CN03921A (enExample) |
| RU (1) | RU2014121304A (enExample) |
| WO (1) | WO2013061295A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104603271B (zh) | 2012-07-03 | 2019-07-19 | 马林生物科技有限公司 | 用于治疗肌肉萎缩症患者的寡核苷酸 |
| EP3315608B1 (en) * | 2015-06-26 | 2020-09-16 | Suzhou Ribo Life Science Co., Ltd. | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof |
| JP6924744B2 (ja) | 2015-07-17 | 2021-08-25 | アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| EP3643706B1 (en) * | 2017-06-16 | 2023-11-15 | Eisai R&D Management Co., Ltd. | Modified nucleic acid monomers and oligonucleic acid analogues, with high biological stability and target gene silencing activity, for use in therapy and diagnosis of cancer and viral diseases |
| HRP20250277T1 (hr) | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| JP7360716B2 (ja) * | 2017-12-01 | 2023-10-13 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 |
| EP3873488B1 (en) * | 2018-10-31 | 2025-03-19 | The University of Sydney | Pharmaceutical compositions for use in treating an hbv or hdv infection |
| JP7507495B2 (ja) | 2018-12-28 | 2024-06-28 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| CN113286888B (zh) | 2019-05-22 | 2023-12-22 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| JP7610848B2 (ja) | 2019-05-22 | 2025-01-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| CN113227376B (zh) | 2019-05-22 | 2024-04-09 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN113795582B (zh) | 2019-05-24 | 2024-05-24 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814614A (zh) * | 2005-02-06 | 2006-08-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 核酸、肽核酸衍生物及它们的用途 |
| US20100209491A1 (en) * | 2007-09-17 | 2010-08-19 | Mogam Biotechnology Research Institute | Method for enhancing serum stability and lowering immune response of sirna down-regulating gene expression of hbv or hcv |
-
2012
- 2012-10-26 CA CA2853609A patent/CA2853609A1/en not_active Abandoned
- 2012-10-26 EP EP12798850.9A patent/EP2771466A1/en not_active Withdrawn
- 2012-10-26 RU RU2014121304/10A patent/RU2014121304A/ru not_active Application Discontinuation
- 2012-10-26 US US14/354,180 patent/US20140350080A1/en not_active Abandoned
- 2012-10-26 CN CN201280053081.0A patent/CN104011209A/zh active Pending
- 2012-10-26 WO PCT/IB2012/055915 patent/WO2013061295A1/en not_active Ceased
- 2012-10-26 AP AP2014007650A patent/AP2014007650A0/xx unknown
- 2012-10-26 BR BR112014010134A patent/BR112014010134A2/pt not_active IP Right Cessation
- 2012-10-26 IN IN3921CHN2014 patent/IN2014CN03921A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2853609A1 (en) | 2013-05-02 |
| AP2014007650A0 (en) | 2014-05-31 |
| RU2014121304A (ru) | 2015-12-10 |
| US20140350080A1 (en) | 2014-11-27 |
| WO2013061295A1 (en) | 2013-05-02 |
| EP2771466A1 (en) | 2014-09-03 |
| CN104011209A (zh) | 2014-08-27 |
| IN2014CN03921A (enExample) | 2015-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Keshavarz et al. | miRNA-based strategy for modulation of influenza A virus infection | |
| Pu et al. | Regulatory network of miRNA on its target: coordination between transcriptional and post-transcriptional regulation of gene expression: M. Pu et al. | |
| Chen et al. | LncRNA, miRNA and lncRNA-miRNA interaction in viral infection | |
| Cai et al. | HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g | |
| Zhao et al. | Identification of cellular microRNA-136 as a dual regulator of RIG-I-mediated innate immunity that antagonizes H5N1 IAV replication in A549 cells | |
| Torres et al. | MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection | |
| JP6311092B2 (ja) | 機能性核酸の安定化法 | |
| IN2014CN03921A (enExample) | ||
| Zhang et al. | Induction of the cellular miR-29c by influenza virus inhibits the innate immune response through protection of A20 mRNA | |
| Piasecka et al. | RNA secondary structure motifs of the influenza A virus as targets for siRNA-mediated RNA interference | |
| WO2020198509A3 (en) | Modified oligonucleotides with increased stability | |
| EA201490993A1 (ru) | МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи | |
| Breuer et al. | What goes around comes around: Artificial circular RNAs bypass cellular antiviral responses | |
| AU2018253578A1 (en) | RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA) | |
| Swaminathan et al. | The role of microRNAs in HIV-1 pathogenesis and therapy | |
| EA201790420A1 (ru) | Средства, представляющие собой модифицированную двухнитевую рнк | |
| BR112015000710A8 (pt) | Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva | |
| BR112012011381B8 (pt) | oligonucleotídeo antisenso antiviral isolado e composição farmacêutica compreendendo o mesmo | |
| WO2012024170A3 (en) | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | |
| MX2020011807A (es) | Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b. | |
| BR112013010525A2 (pt) | tratamento de hbv | |
| Wang et al. | RNA therapeutics targeting osteoclast-mediated excessive bone resorption | |
| BRPI0921096A8 (pt) | Composições e métodos para inibir a expressão dos genes de fator vii | |
| Cui et al. | Identification of cellular microRNA miR-188-3p with broad-spectrum anti-influenza A virus activity | |
| Stoppani et al. | Expression of a single siRNA against a conserved region of NP gene strongly inhibits in vitro replication of different Influenza A virus strains of avian and swine origin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |